References
- Reference annotations
- • Of interest
- •• Of considerable interest
- World Health Organization. [ cited 2015 Jul]. Available from: http://www.who.int/mediacentre/factsheets/fs211/en/
- Karve S, Meier G, Davis KL, et al. Influenza-related health care utilization and productivity losses during seasons with and without a match between the seasonal and vaccine virus B lineage. Vaccine. 2013;31(33):3370–3388.
- Keech M, Beardsworth P. The impact of influenza on working days lost: a review of the literature. Pharmacoeconomics. 2008;26(11):911–924.
- Molinari NA, Ortega-Sanchez IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007;25(27):5086–5096.
- Xue Y, Kristiansen IS, de Blasio BF. Modeling the cost of influenza: the impact of missing costs of unreported complications and sick leave. BMC Public Health. 2010;10:724.
- Centers for Disease Control and Prevention. The Pink Book: Influenza 2012. [cited 2015 Apr]. Available from http://www.cdc.gov/vaccines/pubs/pinkbook/flu.html
- Glezen WP. Emerging infections: pandemic influenza. Epidemiol Rev. 1996;18(1):64–76.
- Zhou H, Thompson WW, Viboud CG, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis. 2012;54(10):1427–1436.
- Centers for Disease Control and Prevention. How the flu virus can change: “drift” and “shift” [ cited 2015 Apr]. Available from: http://www.cdc.gov/flu/about/viruses/change.htm
- Irving SA, Patel DC, Kieke BA, et al. Comparison of clinical features and outcomes of medically attended influenza A and influenza B in a defined population over four seasons: 2004-2005 through 2007-2008. Influenza Other Respir Viruses. 2012;6(1):37–43.
• The findings from this paper demonstrate that symptoms of influenza A and influenza B are identical.
- McCullers JA, Huber VC. Correlates of vaccine protection from influenza and its complications. Hum Vaccin Immunother. 2012;8(1):34–44.
- Rota PA, Wallis TR, Harmon MW, et al. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology. 1990;175(1):59–68.
• The paper provides a comprehensive overview on the entire evolution of the influenza B lineages.
- Centers for Disease Control and Prevention. Influenza season summaries [ cited 2015 Apr]. Available from: http://www.cdc.gov/flu/weekly/pastreports.htm
- Centers for Disease Control and Prevention. Influenza season summaries [ cited 2015 Apr]. Available from: http://www.cdc.gov/flu/weekly/pastreports.htm
- World Health Organization. FluNet (UK) [ cited 2015 May]. Available from http://www.who.int/influenza/gisrs_laboratory/flunet/en/
- Robert Koch Institut. Influenza-assoziierte Mortalität in Deutschland 1985–2006 [ cited 2015 May]. Available at: http://edoc.rki.de/documents/rki_fv/re3BNEVpkzVE/PDF/26k5qbYqF4loFg.pdf
- Robert Koch Institut. Bericht zur Epidemiologie der Influenza in Deutschland Saison 2012/13 [ cited 2015 May]. Available from: https://influenza.rki.de/Saisonberichte/2012.pdf
- World Health Organization. FluNet (Brazil) [ cited 2015 May]. Available from: http://www.who.int/influenza/gisrs_laboratory/flunet/en/
- Paul Glezen W, Schmier JK, Kuehn CM, et al. The burden of influenza B: a structured literature review. Am J Public Health. 2013;103(3):e43–51.
- Centers for Disease Control and Prevention. FluView. Week 16: April 19, 2015 [ cited 2015 May]. Available from: http://www.cdc.gov/flu/weekly/pdf/External_F1513.pdf
- Matias G, Taylor R, Haguinet F, et al. Estimates of age-specific influenza-related mortality and hospitalizations in the United States from 1997 to 2009. Poster presented at Options for the Control of Influenza VIII. Vol. P1–200. 2013 Sep 5–10; Cape Town. p. 146.
- Matias G, Haguinet F, Schuck-Paim C, et al. Model estimates of age-specific influenza-attributable physician office visits in the United States in recent years. Poster presented at The 19th WONCA Europe Conference; 2014 Jul 2–5; Lisbon, Portugal. [cited 2015 May]. Available from: http://www.woncaeurope2014.org/en
- Matias G, Lustig R, Schuck-Paim C, et al. Model estimates of age specific influenza related mortality in the UK in recent years. Poster presented at Influenza Vaccines for the World (IVW 2012); 2012 Oct 9–12; Valencia. [cited 2015 May]. Available from: http://www.meetingsmanagement.co.uk/index.php?option=com_content&view=article&id=6&Itemid=7
- Matias G, Taylor R, Haguinet F, et al. Model estimates of age-specific influenza-related outpatient visits in the UK in recent years. Poster presented at Options for the Control of Influenza VIII. Vol. P1–203. 2013 Sep 5–10; Cape Town. p. 148–149.
- Paget WJ, Balderston C, Casas I, et al. Assessing the burden of paediatric influenza in Europe: the European Paediatric Influenza Analysis (EPIA) project. Eur J Pediatr. 2010;169(8):997–1008.
- Centers for Disease Control and Prevention. Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices--United States, 2013-2014. MMWR Recomm Rep. 2013;62(RR–07):1–43.
•• This is an example of a national authority (US-CDC) acknowledging the clinical value offered by a quadrivalent vaccine.
- Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother. 2012;8(1):81–88.
- Robert Koch Institut, influenza season reports. [ cited 2015 July]. Available from: https://influenza.rki.de/Saisonberichte/2012.pdf
- Robert Koch Institut, influenza season reports. [ cited 2015 Jul]. Available from: https://influenza.rki.de/Saisonberichte/2011.pdf
- Robert Koch Institut, influenza season reports. [ cited 2015 Jul]. Available from: https://influenza.rki.de/Saisonberichte/2010.pdf
- Robert Koch Institut, influenza season reports. [ cited 2015 Jul]. Available from: https://influenza.rki.de/Saisonberichte/2009.pdf
- Robert Koch Institut, influenza season reports. [ cited 2015 Jul]. Available from: https://influenza.rki.de/Saisonberichte/2008.pdf
- Robert Koch Institut, influenza season reports. [ cited 2015 Jul]. Available from: https://influenza.rki.de/Saisonberichte/2007.pdf
- Robert Koch Institut, influenza season reports. [ cited 2015 Jul]. Available from: https://influenza.rki.de/Saisonberichte/2006.pdf
- Robert Koch Institut, influenza season reports. [ cited 2015 Jul]. Available from: https://influenza.rki.de/Saisonberichte/2005.pdf
- Robert Koch Institut, influenza season reports. [ cited 2015 Jul]. Available from: https://influenza.rki.de/Saisonberichte/2004.pdf
- Robert Koch Institut, influenza season reports. [ cited 2015 Jul]. Available from: https://influenza.rki.de/Saisonberichte/2003.pdf
- Robert Koch Institut, influenza season reports. [ cited 2015 Jul]. Available from: https://influenza.rki.de/Saisonberichte/2002.pdf
- Robert Koch Institut, influenza season reports. [ cited 2015 Jul]. Available from: https://influenza.rki.de/Saisonberichte/2001.pdf
- Health Protection Agency. Annual reports [ cited 2015 Jul]. Available from: https://www.gov.uk/government/statistics/annual-flu-reports
- Bricks L, Paiva T, Carvalhanas T, et al. Influenza B circulation in Brazil and characterization of 75 B strains isolated from patients from São Paulo state, Brazil (2002-2013). Abstract 026, presented at ESPID 2014; 2014. [cited 2015 May]. Available from: http://cmoffice.kenes.com/cddemo/data/HtmlApp/main.html#open-authors
- Belshe RB, Coelingh K, Ambrose CS, et al. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine. 2010;28(9):2149–2156.
- Centers fo Disease Control and Prevention. FluView Surveillance Reports Past Seasons (2010–2011 to 2013–2014) [ cited 2015 Apr]. Available from: http://www.cdc.gov/flu/pastseasons/index.htm
- Eiros-Bouza JM, Perez-Rubio A. Burden of influenza virus type B and mismatch with the flu vaccine in Spain. Rev Esp Quimioter. 2015;28(1):39–46.
- Heikkinen T, Ikonen N, Ziegler T. Impact of Influenza B Lineage-Level Mismatch Between Trivalent Seasonal Influenza Vaccines and Circulating Viruses, 1999-2012. Clin Infect Dis. 2014;59(11):1519–1524.
•• A retrospective population-level study of lineage-level mismatch between the vaccine and circulating strains of influenza B viruses showing substantial adverse impact, especially among children and adolescents.
- Carrat F, Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine. 2007;25(39–40):6852–6862.
- Skowronski DM, De Serres G, Dickinson J, et al. Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007. J Infect Dis. 2009;199(2):168–179.
- Skowronski DM, Janjua NZ, Sabaiduc S, et al. Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine. J Infect Dis. 2014;210(1):126–137.
- Menniti-Ippolito F, Da Cas R, Traversa G, et al. Vaccine effectiveness against severe laboratory-confirmed influenza in children: results of two consecutive seasons in Italy. Vaccine. 2014;32(35):4466–4470.
- Heinonen S, Silvennoinen H, Lehtinen P, et al. Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study. Lancet Infect Dis. 2011;11(1):23–29.
- Tricco AC, Chit A, Soobiah C, et al. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med. 2013;11:153.
•• A large meta-analyses demonstrating drop in vaccine efficacy due to B-strain mismatch.
- European Centre for Disease Prevention and Control. Influenza Vaccination [ cited 2015 Aug]. Available from: http://ecdc.europa.eu/en/healthtopics/seasonal_influenza/vaccines/Pages/influenza_vaccination.aspx
- Centers for Disease Control and Prevention. Influenza (Flu) [ cited 2015 Aug]. Available from: http://www.cdc.gov/flu/protect/vaccine/vaccines.htm
- Beran J, Vesikari T, Wertzova V, et al. Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective, randomized, placebo-controlled trial. J Infect Dis. 2009;200(12):1861–1869.
- Pavia-Ruz N, Angel Rodriguez Weber M, Lau YL, et al. A randomized controlled study to evaluate the immunogenicity of a trivalent inactivated seasonal influenza vaccine at two dosages in children 6 to 35 months of age. Hum Vaccin Immunother. 2013;9(9):1978–1988.
- Jackson LA, Gaglani MJ, Keyserling HL, et al. Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons. BMC Infect Dis. 2010;10:71.
- Jain VK, Rivera L, Zaman K, et al. Vaccine for prevention of mild and moderate-to-severe influenza in children. N Engl J Med. 2013;369(26):2481–2491.
- Hannoun C, Megas F, Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res. 2004;103(1–2):133–138.
- Hobson D, Curry RL, Beare AS, et al. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) . 1972;70(4):767–777.
- Center for Biologics Evaluation and Research (CBER). Guidance for Industry: Clinical data needed to support the licensure of seasonal inactivated influenza vaccines. Food and Drug Administration (FDA) [ cited 2015 Jul]. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091990.pdf
- Committee for Proprietary Medicinal Products (CPMP): Note for guidance on harmonisation of requirements for influenza vaccines. The European Agency for the Evaluation of Medicinal Products [ cited 2015 Jul]. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003945.pdf
- Beran J, Peeters M, Dewe W, et al. Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults. BMC Infect Dis. 2013;13:224.
- Kieninger D, Sheldon E, Lin WY, et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged >/=18 years. BMC Infect Dis. 2013;13:343.
- Rodriguez Weber MA, Claeys C, Aranza Doniz C, et al. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age. Pediatr Infect Dis J. 2014;33(12):1262–1269.
- Domachowske JB, Pankow-Culot H, Bautista M, et al. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis. 2013;207(12):1878–1887.
- 115345. GSK Clinical Study Register. [ cited 2015 Aug]. Available from: http://www.gsk-clinicalstudyregister.com/study/115345?study_ids=115345#ps
- Jain VK, Chandrasekaran V, Wang L, et al. A historically-controlled Phase III study in adults to characterize the acceptability of a process change for manufacturing inactivated quadrivalent influenza vaccine. BMC Infect Dis. 2014;14:133.
- Tinoco JC, Pavia-Ruz N, Cruz-Valdez A, et al. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged >/=18 years: a phase III, randomized trial. Vaccine. 2014;32(13):1480–1487.
- Langley JM, Carmona Martinez A, Chatterjee A, et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children. J Infect Dis. 2013;208(4):544–553.
- Langley JM, Wang L, Aggarwal N, et al. Immunogenicity and reactogenicity of an inactivated quadrivalent influenza vaccine administered intramuscularly to children 6 to 35 months of age in 2012–2013: a randomized, double-blind, controlled, multicenter, multicountry, clinical trial. J Pediatric Infect Dis Soc. 2014;4(3):242–251.
- Wang L, Chandrasekaran V, Domachowske JB, et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in US children 6–35 months of age during 2013–2014: results from a phase II randomized trial. J Pediatric Infect Dis Soc. 2015. pii: piv0419. [Epub ahead of print].
- Pebody RG, Andrews N, Fleming DM, et al. Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom. Epidemiol Infect. 2013;141(3):620–630.
- World Health Organization. Recommended composition of influenza virus vaccines for use in the 2012-2013 northern hemisphere influenza season 2012. [cited 2015 Aug]. Available from: http://www.who.int/influenza/vaccines/virus/recommendations/201202_recommendation.pdf?ua=1
- Canada Advisory Committee Statement on Seasonal Influenza Vaccine 2014-2015. [ cited 2015 Aug]. Available from: http://publications.gc.ca/collections/collection_2014/aspc-phac/HP40-114-2014-eng.pdf
- Zhang H, Wang L, Compans RW, et al. Universal influenza vaccines, a dream to be realized soon. Viruses. 2014;6(5):1974–1991.
- Flucelvax. [ cited 2015 Jul]. Available from: http://www.cdc.gov/flu/protect/vaccine/cell-based.htm
- Medicago. Seasonal flu vaccine [ cited 2015 Jul]. Available from: http://www.medicago.com/English/Products/Flu-vaccine/default.aspx